G1 Therapeutics Stock Current Valuation
| GTHXDelisted Stock | USD 7.15 0.00 0.00% |
Valuation analysis of G1 Therapeutics helps investors to measure G1 Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that G1 Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of G1 Therapeutics is based on 3 months time horizon. Increasing G1 Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since G1 Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of GTHX Stock. However, G1 Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 7.15 | Real 5.03 | Hype 7.15 |
The intrinsic value of G1 Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence G1 Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of G1 Therapeutics helps investors to forecast how GTHX stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of G1 Therapeutics more accurately as focusing exclusively on G1 Therapeutics' fundamentals will not take into account other important factors: G1 Therapeutics Company Current Valuation Analysis
G1 Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current G1 Therapeutics Current Valuation | 364.46 M |
Most of G1 Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, G1 Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, G1 Therapeutics has a Current Valuation of 364.46 M. This is 97.46% lower than that of the Biotechnology sector and 92.15% lower than that of the Health Care industry. The current valuation for all United States stocks is 97.81% higher than that of the company.
GTHX Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses G1 Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of G1 Therapeutics could also be used in its relative valuation, which is a method of valuing G1 Therapeutics by comparing valuation metrics of similar companies.G1 Therapeutics is currently under evaluation in current valuation category among its peers.
GTHX Fundamentals
| Return On Equity | -1.09 | |||
| Return On Asset | -0.19 | |||
| Profit Margin | (0.77) % | |||
| Operating Margin | (0.21) % | |||
| Current Valuation | 364.46 M | |||
| Shares Outstanding | 52.76 M | |||
| Shares Owned By Insiders | 10.92 % | |||
| Shares Owned By Institutions | 54.61 % | |||
| Number Of Shares Shorted | 3.41 M | |||
| Price To Earning | (1.95) X | |||
| Price To Book | 15.34 X | |||
| Price To Sales | 6.48 X | |||
| Revenue | 82.51 M | |||
| Gross Profit | 47.55 M | |||
| EBITDA | (39.01 M) | |||
| Net Income | (47.97 M) | |||
| Cash And Equivalents | 143.96 M | |||
| Cash Per Share | 3.37 X | |||
| Total Debt | 57.17 M | |||
| Debt To Equity | 1.24 % | |||
| Current Ratio | 4.75 X | |||
| Book Value Per Share | 0.47 X | |||
| Cash Flow From Operations | (38.34 M) | |||
| Short Ratio | 1.01 X | |||
| Earnings Per Share | (0.86) X | |||
| Target Price | 7.15 | |||
| Number Of Employees | 100 | |||
| Beta | 1.68 | |||
| Market Capitalization | 377.22 M | |||
| Total Asset | 121.54 M | |||
| Retained Earnings | (779.99 M) | |||
| Working Capital | 85.23 M | |||
| Current Asset | 252.33 M | |||
| Current Liabilities | 9.86 M | |||
| Net Asset | 121.54 M |
About G1 Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze G1 Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of G1 Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of G1 Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Consideration for investing in GTHX Stock
If you are still planning to invest in G1 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the G1 Therapeutics' history and understand the potential risks before investing.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |